Loading
Latest filing published 06 Jun 2024 for Cara Therapeutics, Inc..
Not enough buy signals with a settled T+90 horizon to measure a track record yet.
No signal scores available.
This profile gathers the share dealings of Martin Vogelbaum across 2 companies, led by Tvardi Therapeutics, Inc. and NephroGenex, Inc. Over a trading history stretching from 5 February 2014 to 4 June 2024, the count stands at 18 filings.
The open-market side counts 3 purchases for €3.6M alongside 3 sales for €285k. The net balance comes to €3.3M on the buying side. Open-market purchases are the filings investors watch most closely, because the insider pays for the shares out of pocket. The rest of the record consists of 9 share grants.
A typical purchase (the median) is worth €1.1M.
Most recently, on 6 June 2024, the filings show a share grant in Tvardi Therapeutics, Inc. The last insider purchase was made public on 18 March 2016, 3,872 days ago. Typically, a trade is published a median of 3 days after it takes place. For comparison, the SEC allows two business days to file a Form 4. Every figure here comes from the filings published by SEC (Form 4) and describes the past, not future prices; it is not investment advice.
Open company profiles for insider transactions, fundamentals and analyst consensus when available.
5 of 5 declarations